Advertisement
Person › Details
Peer M. Schatz (PS Capital Management GmbH (Peer Schatz))
Schatz, Peer M. (Resolve BioSciences 202012 Chairman + Co-Founder before Qiagen 1993–201910 CEO RESIGNED 10/19)
Organisation | PS Capital Management GmbH (Peer Schatz) | |
Former/major organisation | Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) | |
Group | Qiagen (Group) | |
Product | Molecular Cartography™ technology | |
Product 2 | sample preparation (technology) | |
Resolve Biosciences GmbH. (12/10/20). "Press Release: Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis". Monheim.
Company announces $24 million Series A financing and appoints Jason T. Gammack as CEO to accelerate development and commercialization of Molecular Cartography™ platform
Resolve Biosciences, the pioneer in Molecular Cartography™, announced the completion of a $24 million Series A financing round and the appointment of Co-founder Jason T. Gammack as Chief Executive Officer.
[picture ] Detection of 500,000 mRNA Transcripts from 100 different genes in a mouse cortex tissue using Resolve Biosciences’ Molecular Cartography™ platform.
Credentials: Resolve Biosciences, Courtesy of Araks Martirosyan (Matthew Holt lab, VIB-KU Leuven, Belgium)
The company’s Molecular Cartography platform is a groundbreaking multi-analyte and highly multiplex spatial analysis technology that enables scientists to resolve the most daunting biological challenges in areas such as oncology, neuroscience, and infectious disease. It produces deep contextual data sets that illuminate molecular interactions at subcellular resolution, while preserving the sample tissue. The initial applications of Resolve’s Molecular Cartography platform deliver the highest-resolution view of transcriptomic activity and provide the ability to interrogate hundreds of genes in a single run. Future solutions will add DNA, protein, and metabolomic data layers. Unlike current approaches, Resolve’s technology provides the required sensitivity, specificity, and workflow convenience to elucidate the cell’s complex transcriptional landscape.
Series A Financing
The Series A financing round was led by PS Capital Management and MasterMind Advisory Services and included participation from Alafi Capital, John Shoffner, and High Tech Gründerfonds. The company will use the proceeds to accelerate product development and drive industry adoption of its Molecular Cartography technology.
“Molecular Cartography creates a new dimension of spatial analysis, which will soon expand the frontiers of modern molecular biology. Our innovative solution enables valuable scientific insights that far exceed the reach of legacy spatial biology technologies,” said Peer M. Schatz, Chairman and Co-founder of Resolve Biosciences. “Jason is an accomplished leader in the field of advanced genomics, and I’m looking forward to working with him again to help Resolve Biosciences transform the future of life sciences research and clinical diagnostics.”
CEO Appointment
Jason T. Gammack brings more than 25 years of life sciences industry experience and has developed successful product and customer engagement strategies for some of its preeminent biotechnology brands. He recently served as Chief Commercial Officer at Inscripta, where he oversaw sales, marketing, business development, and customer support for the company’s CRISPR-enabled Onyx™ Digital Genome Engineering platform. Before that, he was Vice President of the Life Science Business at QIAGEN, where he led the life science portfolio and go-to-market strategy. Earlier in his career, Gammack developed commercialization growth strategies at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corporation.
“Resolve Biosciences’ pioneering Molecular Cartography platform powers novel insights by enabling scientists to gain the highest-resolution view of subcellular gene expression activity,” said Gammack. “Together with our talented team of scientists and investors, we are poised to lead the next generation of single-cell analysis and support scientists around the world as they apply the latest advances of our Molecular Cartography technology platform to solve the most complex biological questions.”
About Resolve Biosciences
Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company’s proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program. Resolve Biosciences is privately held and headquartered in Monheim, Germany. For additional information, visit www.resolve-biosciences.com.
Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences Inc.
Media Contact
Andrew Noble
+1 (415) 722-2129
andrew@bioscribe.com
Record changed: 2022-11-18 |
Advertisement
More documents for Peer M. Schatz
- [1] Centogene N.V.. (2/28/24). "Press Release: Centogene Explores Strategic Alternatives". Cambridge, MA, Rostock & Berlin....
- [2] Relation Therapeutics Ltd.. (6/9/22). "Press Release: Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTO". London....
- [3] Centogene N.V.. (2/1/22). "Press Release: Centogene Announces Nomination of Kim Stratton as Chief Executive Officer". Cambridge, MA, Rostock & Berlin....
- [4] Siemens Healthineers AG. (1/5/21). "Press Release: Siemens Healthineers Proposes Peer Schatz to Annual Shareholders' Meeting as New Supervisory Board Member". Erlangen....
- [5] Resolve Biosciences GmbH. (12/10/20). "Press Release: Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis". Monheim....
- [6] Illumina, Inc.. (10/7/19). "Press Release: Illumina and Qiagen Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests". San Diego, CA & Hilden & Germantown, MD....
- [7] Qiagen N.V.. (10/7/19). "Press Release: Qiagen Announces CEO Leadership Transition. Peer M. Schatz to Step Down as CEO to Pursue New Opportunities". Venlo....
- [8] Qiagen N.V.. (5/16/19). "Press Release: Qiagen and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions". Hilden, Germantown, MD & Plymouth Meeting, PA....
- [9] Qiagen N.V.. (2/4/19). "Press Release: Qiagen Reports Results for Fourth Quarter and Full-year 2018". Venlo....
- [10] Formulatrix, Inc.. (1/10/19). "Press Release: Formulatrix Digital PCR Technology to Be Acquired by Qiagen". Bedford, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top